You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》科濟藥業(02171.HK)下周一起招股 引入禮來等9名基投
阿思達克 06-04 17:54
內地生物製藥公司科濟藥業(02171.HK)公布招股詳細,計劃發行9,474.7萬股,當中10%為本地發售,90%為國際配售,每股招股價介乎29.6至32.8元,集資最多約31.07億元。每手500股入場費約16,565.26元,聯席保薦人為高盛及瑞銀。

招股期由下周一(7日)起至下周四(10日)結束,料於6月18日上市。是次招股共引入9名基石投資者,包括禮來亞洲基金、新華人壽、CloudAlpha、睿遠、WT基金、廣發証券、Dymon Asia、常春藤及南方基金,合共認購約17.85億元或2.3億美元等值股份,設6個月禁售期。

財務高級副總裁謝嵐表示,由於公司尚未有產品商業化,因此過往幾年錄得經營虧損,去年度虧損達10.64億元人民幣,料於明年上半年就核心產品CT053提交中國新藥上市申請。

問到與熱門新股時代天使(06699.HK)撞期,董事會主席、首席執行官兼首席科學官李宗海稱,每家公司都有特點,投資者亦有不同關注重點,又指在研產品於臨床實驗中顯示出有療效及安全性,相信會得到市場認可。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account